<DOC>
	<DOC>NCT02392624</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled study will evaluate efficacy and safety of subcutaneous omalizumab as an add-on therapy through 48 weeks. After completing an initial 24-week open-label treatment period with omalizumab 300 mg every 4 weeks, participants responding to omalizumab will be randomized at a 3:2 ratio (omalizumab:placebo) to either continue omalizumab or be transitioned to placebo for a further 24 weeks.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Adolescents and adults of age group 1275 years Diagnosis of CIU refractory to H1 antihistamines at baseline Presence of itch and hives for at least 8 consecutive weeks before enrollment despite current use of H1 antihistamine treatment (up to four times the approved dose) during this time period Receiving H1 antihistamine treatment (up to four times the approved dose) for CIU for at least 3 consecutive days immediately prior to screening visit with continued current use on the day of the initial screening CIU diagnosis of greater than or equal to 6 months Willing and able to complete a daily symptom eDiary for the duration of the study Treatment with an investigational agent within 30 days of the initial screening visit Body weight less than (&lt;) 20 kilograms (kg) Clearly defined underlying etiology for chronic urticarias other than CIU Evidence of a parastic infection Atopic dermatitis or other skin disease associated with pruritus Previous treatment with omalizumab within 1 year prior to screening Participants may not have taken during treatment period or have been taking within 30 days before screening any of the following medications/treatments: regular (daily/every other day) hydroxychloroquine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide, Intravenous Immunoglobulin G (IVIG) or plasmapheresis Regular (daily/every other day) doxepin (oral) use within 14 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>